Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Treatment Patterns and Clinical Outcomes of Chronic Urticaria : Two-year Follow-up Results from the Scandinavian AWARE Study. / Thomsen, Simon F.; Pritzier, Ellen C.; Anderson, Chris D.; Juvik, Siri; Baust, Nicolas V.; Dodge, Rikke; Dahlborn, Anna Karin; Vestergaard, Christian.
I: Acta Dermato-Venereologica, Bind 102, adv00689, 2022, s. 1-6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment Patterns and Clinical Outcomes of Chronic Urticaria
T2 - Two-year Follow-up Results from the Scandinavian AWARE Study
AU - Thomsen, Simon F.
AU - Pritzier, Ellen C.
AU - Anderson, Chris D.
AU - Juvik, Siri
AU - Baust, Nicolas V.
AU - Dodge, Rikke
AU - Dahlborn, Anna Karin
AU - Vestergaard, Christian
N1 - Publisher Copyright: © 2022, Medical Journals/Acta D-V. All rights reserved.
PY - 2022
Y1 - 2022
N2 - The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investiga-ted outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on pa-tients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from base-line, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the re-sult of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and con-trol at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.
AB - The AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study investiga-ted outcomes in patients with chronic urticaria refractory to H1-antihistamine. The objective of the current study was to analyse the effects of treatment on pa-tients’ symptoms and quality of life for a period of up to 2 years. Over the 2 years, there was clear improvement in the high rates of disease burden from base-line, as evidenced by lower scores for disease severity scales, better quality of life, and a decreasing rate of medical resource utilization. However, this is the re-sult of treatment adherence to the guidelines in highly specialized Scandinavian urticaria centres, and has its basis in the relatively low treatment intensity and con-trol at enrolment. There is a need for greater adherence to the treatment guidelines and better management of antihistamine-refractory chronic urticaria.
KW - AWARE
KW - chronic urticaria
KW - omalizumab
KW - patient-reported outcomes
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85128248249&partnerID=8YFLogxK
U2 - 10.2340/actadv.v102.1620
DO - 10.2340/actadv.v102.1620
M3 - Journal article
C2 - 35166853
AN - SCOPUS:85128248249
VL - 102
SP - 1
EP - 6
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
M1 - adv00689
ER -
ID: 311619109